Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

On CNBC's “ Halftime Report Final Trades ,” Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. GILD +0.78% Get Free Report is one of the best-performing names in one of the best-performing ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

As the sixth and final season of The Handmaid’s Tale is nearing its premiere next week, production on its sequel series The ...

The Testaments also rounds out its cast with 9 new actors: Mabel Li, Amy Seimetz, Brad Alexander, Zarrin Darnell-Martin, Eva ...